journal
MENU ▼
Read by QxMD icon Read
search

Urologic Oncology

journal
https://www.readbyqxmd.com/read/28433471/is-transurethral-resection-alone-enough-for-the-diagnosis-of-histological-variants-a-single-center-study
#1
Marco Moschini, Shahrokh F Shariat, Massimo Freschi, Francesco Soria, David D'Andrea, Mohammad Abufaraj, Beat Foerster, Paolo Dell'Oglio, Emanuele Zaffuto, Agostino Mattei, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Andrea Gallina, Renzo Colombo
INTRODUCTION: To evaluate incidence of histological variants and grade agreement between transurethral resection (TUR) and radical cystectomy (RC) in patients with bladder cancer. METHODS: A total of 779 patients treated with TUR and subsequently with RC between 1990 and 2013 at a single center were analyzed retrospectively. Variant histology classifications used in our analyses were sarcomatoid, small cell, squamous, or micropapillary. Grade agreement was calculated using the Cohen kappa coefficient...
April 19, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28427860/differential-mtor-pathway-profiles-in-bladder-cancer-cell-line-subtypes-to-predict-sensitivity-to-mtor-inhibition
#2
Andrew M Hau, Manando Nakasaki, Kazufumi Nakashima, Goutam Krish, Donna E Hansel
BACKGROUND: Molecular classification of bladder cancer has been increasingly proposed as a potential tool to predict clinical outcomes and responses to chemotherapy. Here we focused on mechanistic target of rapamycin (mTOR) inhibition as a chemotherapeutic strategy and characterized the expression profile of mTOR signaling targets in representative bladder cancer cell lines from basal, luminal, and either basal/luminal ("non-type") molecular subtypes. MATERIALS AND METHODS: Protein and mRNA expression of mTOR signaling components from representative luminal (RT4 and RT112), basal (SCaBER and 5637), and nontype (T24 and J82) bladder cancer cell line subtypes were determined by Western blot and database mining analysis of the Cancer Cell Line Encyclopedia...
April 18, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28427859/the-role-of-c-met-in-prognosis-and-clinicopathology-of-renal-cell-carcinoma-results-from-a-single-centre-study-and-systematic-review
#3
Shouzhen Chen, Yaofeng Zhu, Jianfeng Cui, Yong Wang, Yangyang Xia, Jing Song, Shanshan Cheng, Changkuo Zhou, Dongqing Zhang, Bing Zhang, Benkang Shi
BACKGROUND AND OBJECTIVES: The c-Met proto-oncogene pathway plays an important role in the progression of various cancers. However, the effect of the c-Met pathway on renal cell carcinoma (RCC) remains controversial. We decided to clarify the role of c-Met in prognosis and clinicopathology of RCC. METHODS: A total of 10 pairs of tumour and adjacent tissues were obtained from patients with primary RCC between 2013 and 2014 and tissue microarrays to assess c-Met expression in tumour tissues from 90 patients with RCC by Western blot and immunohistochemical staining...
April 18, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28416109/positive-surgical-margins-increase-risk-of-recurrence-after-partial-nephrectomy-for-high-risk-renal-tumors-shah-ph-moreira-dm-okhunov-z-patel-vr-chopra-s-razmaria-aa-alom-m-george-ak-yaskiv-o-schwartz-mj-desai-m-vira-ma-richstone-l-landman-j-shalhav-al-gill
#4
Oleksandr N Kryvenko
PURPOSE: The clinical significance of a positive surgical margin after partial nephrectomy remains controversial. The association between positive margin and risk of disease recurrence in patients with clinically localized renal neoplasms undergoing partial nephrectomy was evaluated. MATERIALS AND METHODS: A retrospective multi-institutional review of 1,240 patients undergoing partial nephrectomy for clinically localized renal cell carcinoma between 2006 and 2013 was performed...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28416108/tumor-necrosis-adds-prognostically-significant-information-to-grade-in-clear-cell-renal-cell-carcinoma-a-study-of-842-consecutive-cases-from-a-single-institution-khor-ly-dhakal-hp-jia-x-reynolds-jp-mckenney-jk-rini-bi-magi-galluzzi-c-przybycin-cg-am-j-surg
#5
Oleksandr N Kryvenko
Tumor necrosis has been shown to be an independent predictor of adverse outcome in renal cell carcinoma. A modification of the International Society of Urological Pathology (ISUP) grading system for renal cell carcinomas has recently been proposed, which incorporates the presence of tumor necrosis into grade. The investigators proposing this system found that necrosis added significant prognostic information to ISUP grade. We attempted to describe our experience with the effect of tumor necrosis in relationship to nuclear grade by reviewing the slides from a large consecutive series of localized clear cell renal cell carcinomas from our institution and obtaining long-term clinical follow-up information (overall survival)...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28416107/characteristics-of-the-peritumoral-pseudocapsule-vary-predictably-with-histologic-subtype-of-t1-renal-neoplasms-jacob-jm-williamson-sr-gondim-dd-leese-ja-terry-c-grignon-dj-boris-rs-urology-november-2015-86-5-956-961
#6
Oleksandr N Kryvenko
OBJECTIVE: To determine characteristics of the peritumoral pseudocapsule (PC) between renal tumor subtypes. METHODS: The peritumoral PCs of 160 pT1 renal tumors were examined, including 60 clear cell renal cell carcinomas (RCCs), 50 papillary RCCs, 25 chromophobe RCCs, and 25 oncocytoma. Pathologic features (presence or absence of PC, mean thickness, continuity, and invasion by tumor) were analyzed. PC thickness was measured using an ocular micrometer to the nearest 1/10mm...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28416106/categorizing-renal-oncocytic-neoplasms-on-core-needle-biopsy-a-morphologic-and-immunophenotypic-study-of-144-cases-with-clinical-follow-up-alderman-ma-daignault-s-wolf-js-jr-palapattu-gs-weizer-az-hafez-ks-kunju-lp-wu-aj-hum-pathol-september-2016-55-1-10
#7
Oleksandr N Kryvenko
There is limited literature on renal oncocytic neoplasms diagnosed on core biopsy. All renal oncocytic neoplasm core biopsies from 2006 to 2013 were, retrospectively, reviewed. Morphologic features and an immunohistochemical panel of CK7, c-KIT, and S100A1 were assessed. Concordance with resection diagnosis, statistical analysis including a random forest classification, and follow-up were recorded. The postimmunohistochemical diagnoses of 144 renal oncocytic core biopsies were favor oncocytoma (67%), favor renal cell carcinoma (RCC) (12%), and cannot exclude RCC (21%)...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28416105/do-clear-cell-papillary-renal-cell-carcinomas-have-malignant-potential-diolombi-ml-cheng-l-argani-p-epstein-ji-am-j-surg-pathol-december-2015-39-12-1621-1634
#8
Oleksandr N Kryvenko
There have been no recurrences or metastases of clear cell papillary renal cell carcinoma (CCPRCC) in 268 reported cases with follow-up in the English-language literature. We identified all our cases of CCPRCC (1990-2013), reviewing all cases that preceded the formal designation of the entity. Immunohistochemical stains were performed on 32 cases during their initial workup. In addition, stains for carbonic anhydrase IX and cytokeratin 7 were performed on 2 cases, one with atypical follow-up and the other with a more compact morphology, although not performed initially...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28416104/multilocular-cystic-renal-cell-carcinoma-pathological-t-staging-makes-no-difference-to-favorable-outcomes-and-should-be-reclassified-bhatt-jr-jewett-ma-richard-po-kawaguchi-s-timilshina-n-evans-a-alibhai-s-finelli-a-j-urol-november-2016-196-5-1350-1355
#9
Oleksandr N Kryvenko
OBJECTIVE: We evaluated survival outcomes of cystic/multilocular cystic renal cell carcinomas in a long-term population-based study based on size and pathological tumor stage. MATERIALS AND METHODS: We, retrospectively, reviewed a provincial cancer registry of all histologically proven cases of multilocular cystic renal cancers treated surgically between 1995 and 2008. All cases of cystic necrosis were excluded from study. Primary end points were overall- and cancer-specific survival estimated using Kaplan-Meier curves...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28412027/regionalization-of-radical-cystectomy-in-the-united-states
#10
Christopher B Anderson, Renee Gennarelli, Harry W Herr, Elena B Elkin
PURPOSE: Radical cystectomy (RC) has become increasingly regionalized to high-volume hospitals. Our objective was to describe changes in regional market concentration and the distribution of RCs among hospitals, and examine how these changes affect patient travel distance to surgery. MATERIALS AND METHODS: We used the surveillance, epidemiology, and end results-Medicare database to identify patients who had RC for bladder cancer from 2001 to 2011. We defined RC market concentration within each Hospital Referral Regions (HRR) in surveillance, epidemiology, and end results using the Hirschman-Herfindhal Index...
April 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28410987/alkaline-phosphatase-velocity-predicts-overall-survival-and-bone-metastasis-in-patients-with-castration-resistant-prostate-cancer
#11
Kai H Hammerich, Timothy F Donahue, Inger L Rosner, Jennifer Cullen, Huai-Ching Kuo, Lauren Hurwitz, Yongmei Chen, Melanie Bernstein, Jonathan Coleman, Daniel C Danila, Adam R Metwalli
INTRODUCTION AND OBJECTIVES: Identifying patients with prostate cancer (CaP) who will ultimately develop bone metastasis (BM) or die of disease is essential. Alkaline phosphatase velocity (APV) has been shown to predict overall survival (OS) and bone metastasis-free survival (BMFS) in an earlier study of an equal access military patient cohort of patients with castrate-resistant prostate cancer (CRPC). To confirm these findings, we examined a cohort of patients from a high-volume cancer center to validate a previous observation that faster alkaline phosphatase (AP) kinetics are predictive of OS and BMFS in this second cohort of patients...
April 11, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28410986/predictors-of-biochemical-recurrence-after-primary-focal-cryosurgery-hemiablation-for-localized-prostate-cancer-a-multi-institutional-analytic-comparison-of-phoenix-and-stuttgart-criteria
#12
Michael Kongnyuy, Michael J Lipsky, Shahidul Islam, Dennis J Robins, Shaun Hager, Daniel M Halpern, Kaitlin E Kosinski, Jeffrey T Schiff, Anthony T Corcoran, Sven Wenske, Aaron E Katz
BACKGROUND: The Phoenix definition (PD) and Stuttgart definition (SD) designed to determine biochemical recurrence (BCR) in patients with postradiotherapy and high-intensity focused ultrasound organ-confined prostate cancer are being applied to follow patients after cryosurgery. We sought to identify predictors of BCR using the PD and SD criteria in patients who underwent primary focal cryosurgery (PFC). MATERIALS AND METHODS: We performed a retrospective review of patients who underwent PFC (hemiablation) at 2 referral centers from 2000 to 2014...
April 11, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28408296/percutaneous-radiofrequency-ablation-for-renal-cell-carcinoma-vs-partial-nephrectomy-comparison-of-long-term-oncologic-outcomes-in-both-clear-cell-and-non-clear-cell-of-the-most-common-subtype
#13
Ning Liu, Daoguang Huang, Xiangming Cheng, Yankun Chong, Wei Wang, Weidong Gan, Hongqian Guo
OBJECTIVES: To compare the clinical outcomes of percutaneous radiofrequency ablation (PRFA) and partial nephrectomy (PN) in patients with clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) of the most common subtypes. MATERIALS AND METHODS: A retrospective study was conducted to review the records of all the patients who underwent PRFA or PN between February 2005 and April 2014 at our institution. Patients with histologic confirmation of ccRCC, papillary RCC, and chromophobe RCC were included...
April 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28408295/genomic-alterations-as-predictors-of-survival-among-patients-within-a-combined-cohort-with-clear-cell-renal-cell-carcinoma-undergoing-cytoreductive-nephrectomy
#14
Daniel M Tennenbaum, Brandon J Manley, Emily Zabor, Maria F Becerra, Maria I Carlo, Jozefina Casuscelli, Almedina Redzematovic, Nabeela Khan, Maria E Arcila, Martin H Voss, Darren R Feldman, Robert J Motzer, Nicole E Benfante, Jonathan A Coleman, Paul Russo, James J Hsieh, Abraham Ari Hakimi
PURPOSE: To establish prognostic genomic biomarkers for patients with metastatic clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: We identified 60 patients who presented with metastatic ccRCC at our institution between 2001 and 2015 and had genomic sequencing on their primary tumor. We pooled these patients with 107 other patients with the same inclusion criteria from three well-known public databases. Five commonly mutated genes were chosen for analysis: VHL, PBRM1, BAP1, SETD2, and KDM5C...
April 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28391998/does-smoking-change-expression-patterns-of-the-tumor-suppressor-and-dna-repair-genes-in-the-prostate-gland
#15
Cetin Boran, Engin Kandirali, Serdar Yanik, Hilal Ahsen, Emre Ulukaradağ, Fahri Yilmaz
OBJECTIVES: Somatic mutations can be present in clonally expanded cell populations in nonmalignant tissues, which are detectable at tissue-level resolution. Some of the mutational changes may arise due to smoking. We aimed to find out changes in carcinogenic gene expressions related to smoking in nonmalignant prostate gland epithelia. MATERIALS AND METHODS: The patients who came to the Department of Urology at Abant Izzet Baysal University Medical Faculty from December 2006 to December 2009 for prostate biopsy were questioned for cigarette smoking...
April 6, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28391999/trends-in-management-of-the-small-renal-mass-in-renal-transplant-recipient-candidates-a-multi-institutional-survey-analysis
#16
Alp Tuna Beksac, David J Paulucci, John P Sfakianos, Balaji N Reddy, Greg E Gin, Susan M Lerner, Ketan K Badani
INTRODUCTION: Patients with end-stage renal disease are under increased risk for renal cell carcinoma development, and radical nephrectomy is the preferred treatment in this setting. Owing to the increased surgical morbidity and mortality, active surveillance (AS) may be a valid option for treatment of small renal masses (SRM). As there is a lack of high-level evidence for treatment recommendations, we performed a survey analysis to analyze the treatment patterns of transplant surgeons...
April 5, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28389159/validation-of-the-ezrin-ck20-and-ki-67-as-potential-predictive-markers-for-bcg-instillation-therapy-of-non-muscle-invasive-bladder-cancer
#17
Per-Uno Malmström, Tammer Hemdan, Ulrika Segersten
OBJECTIVE: The aim of our study was to try to validate 3 promising predictive biomarkers in a database based on prospective trials comparing bacillus Calmette-Guerin (BCG) with mitomycin-C and a combination of epirubicin and interferon, respectively. BACKGROUND: The most common form of bladder cancer is non-muscle-invasive tumors treated initially with transurethral resection. Unfortunately more than half recur and some also progress. Consequently, an attempt to prevent poor outcome is frequently made by intravesical instillations either by chemo- or immunotherapy...
April 4, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28385611/description-of-the-eurotarget-cohort-a-european-collaborative-project-on-targeted-therapy-in-renal-cell-cancer-genetic-and-tumor-related-biomarkers-for-response-and-toxicity
#18
Loes F M van der Zanden, Sita H Vermeulen, Arna Oskarsdottir, Jake S F Maurits, Meta H M Diekstra, Valentin Ambert, Anne Cambon-Thomsen, Daniel Castellano, Achim Fritsch, Jesus Garcia Donas, Rosa Guarch Troyas, Henk-Jan Guchelaar, Arndt Hartmann, Christina Hulsbergen-van de Kaa, Ulrich Jaehde, Kerstin Junker, Anna Martinez-Cardus, Gisli Masson, Jeannette Oosterwijk-Wakka, Marius T Radu, Thorunn Rafnar, Cristina Rodriguez-Antona, Max Roessler, Rob Ruijtenbeek, Kari Stefansson, Anne Warren, Lodewyk Wessels, Tim Eisen, Lambertus A L M Kiemeney, Egbert Oosterwijk
OBJECTIVE: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort...
April 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28366272/clinical-comparison-of-noninvasive-urine-tests-for-ruling-out-recurrent-urothelial-carcinoma
#19
Yair Lotan, Paul OʼSullivan, Jay D Raman, Sharokh F Shariat, Laimonis Kavalieris, Chris Frampton, Parry Guilford, Carthika Luxmanan, James Suttie, Henry Crist, Douglas Scherr, Scott Asroff, Evan Goldfischer, Jeffrey Thill, David Darling
OBJECTIVE: Patients with urothelial carcinoma (UC) undergo rigorous surveillance for recurrence. Noninvasive urine tests are not currently recommended by guideline panels owing to insufficient clinical benefit. The objective of this study was to prospectively compare the performance of the Cxbladder Monitor test to other commonly available urine markers and cytology for surveillance of patients with UC. METHODS AND MATERIALS: A total of 1,036 urine samples were collected from 803 patients undergoing surveillance for UC...
March 30, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28366271/targeted-therapies-in-the-treatment-of-urothelial-cancers
#20
REVIEW
Jeanny B Aragon-Ching, Donald L Trump
Progress has been slow in systemic management of locally advanced and metastatic bladder cancer over the past 20 years. However, the recent approval of immunotherapy with atezolizumab and nivolumab for second-line salvage therapy may usher in an era of more rapid improvement. Systemic treatment is suboptimal and is an area of substantial unmet medical need. The recent findings from The Cancer Genome Atlas project revealed promising pathways that may be amenable to targeted therapies. Promising results with treatment using vascular endothelial growth factor inhibitors such as ramucirumab, sunitinib or bevacizumab, and human epidermal growth factor receptor 2 targeted therapies, epidermal growth factor receptor inhibitors, and fibroblast growth factor receptor inhibitors, are undergoing clinical trials and are discussed later...
March 30, 2017: Urologic Oncology
journal
journal
32958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"